Dataset Information

Plasma proteomics reveals the confounding effect of heparin administration on the analysis of candidate cardiovascular biomarkers - Cohort1

ABSTRACT: Several plasma proteins have been suggested as markers for a variety of cardiovascular conditions but fail to qualify in independent patient cohorts. One reason may relate to interference of medication on plasma protein levels. In the present study we applied a proteomic approach to identify plasma proteins that changed in concentration with heparin administration and therefore potentially may confound their as biomarkers in situations where heparin is used.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Plasma

DISEASE(S): Acute Myocardial Infarction

SUBMITTER: Hans Christian Beck

LAB HEAD: Hans Christian Beck

PROVIDER: PXD008467 | Pride | 2018-10-02

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 306

Publications

Proteomic Discovery and Validation of the Confounding Effect of Heparin Administration on the Analysis of Candidate Cardiovascular Biomarkers.

Beck Hans C HC Jensen Lisette O LO Gils Charlotte C Ilondo Albertine M M AMM Frydland Martin M Hassager Christian C Møller-Helgestad Ole K OK Møller Jacob E JE Rasmussen Lars M LM

Clinical chemistry 20180816 10

<h4>Background</h4>Several plasma proteins have been suggested as markers for a variety of cardiovascular conditions but fail to qualify in independent patient cohorts. This may relate to interference of medication on plasma protein concentrations. We used proteomics to identify plasma proteins that changed in concentration with heparin administration and therefore potentially may confound their evaluation as biomarkers in situations in which heparin is used.<h4>Methods</h4>We used a proteomic a ...[more]

PMID: 30115630

Similar Datasets

Project description:Fish oil supplementation is generally seen as beneficial for human health, due to the presence of n-3 polyunsaturated fatty acids (n-3 PUFAs). These fatty acids can elicit their effect through changes in gene expression. Effects of n-3 PUFAs on gene expression of inflammatory and atherogenic markers have been shown in several in vitro and animal studies. However, little evidence is available on human in vivo studies on n-3 PUFA related gene expression. In the present study we investigate the effects of EPA and DHA supplementation for 6 months on gene expression profiles of peripheral blood mononuclear cells (PBMCs). Whole genome microarray analysis was performed on PBMC RNA from subjects who received 1.8 grams of EPA and DHA in capsules (n=23) or capsules containing high oleic acid sunflower oil (HOSF)(n=25). Intake of EPA and DHA resulted in a change of 1040 genes. We found a down-regulation in inflammatory and atherogenic related pathways, such as NF-ÎºB signaling, eicosanoid synthesis, scavenger receptors activity and cell adhesion. These results seem to point to an improvement in health status, in which lymphocytes are less prone to produce chemokines and adhesion molecules and monocytes show reduced susceptibility to differentiate into foam cells. Overall, beneficial effects of n-3 PUFAs that have been described in vitro and in animal studies, were shown in vivo in human subjects in this study. This not only confirms that EPA and DHA elicits beneficial effects on inflammatory and atherogenic processes of elderly subjects, but also shows that PBMC gene expression profiles can be used to show effects of nutrition on human health status. Fasting venous blood samples were collected at baseline and after 26 weeks of supplementation with either 1.8 g EPA and DHA or HOSF. 4 ml blood was collected for PBMC isolation, using BD Vacutainer Cell Preparation Tubes with sodium citrate (BD, Breda, The Netherlands). Immediately after blood collection PBMCs were isolated according to the manufacturerâs manual. PBMC RNA was isolated from all PBMC samples using Qiagen RNeasy Micro kit (Qiagen, Venlo, the Netherlands). Total RNA from PBMCs from 48 subjects was labeled using a one-cycle cDNA labeling kit (MessageAmpTM II-Biotin Enhanced Kit, Ambion, Inc.) and hybridized to custom designed NuGO GeneChip arrays.

			Action	DRS
	ABA_PILOT_1_BA10_1.raw	Raw
	ABA_PILOT_1_BA10_2.raw	Raw
	ABA_PILOT_1_BA11_1.raw	Raw
	ABA_PILOT_1_BA11_2.raw	Raw
	ABA_PILOT_1_BA12_1.raw	Raw